ArticleJournal of experimental & clinical cancer research : CR2024

Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.

Prachi Bajpai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.